Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mivebresib (AbbVie Inc.)
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mivebresib (ABBV-075) is an orally bioavailable, small-molecule pan-inhibitor of the bromodomain and extra-terminal (BET) family of proteins, including BRD2, BRD4, and BRDT. Developed by AbbVie, it functions as an epigenetic modulator by binding to the bromodomains of BET proteins, which are "readers" of acetylated lysine residues on histone tails. By preventing BET proteins from binding to chromatin, mivebresib inhibits the transcription of key oncogenic drivers such as MYC. It has been investigated in Phase 1 clinical trials for the treatment of advanced solid tumors (including breast, prostate, and lung cancers) and hematologic malignancies (such as acute myeloid leukemia and multiple myeloma), both as a monotherapy and in combination with other agents like venetoclax.
- Other names
- Mivebresib
02
Targets
CREBBP (CREB-binding protein)BRD4 (Bromodomain-containing protein 4)BRDT (Bromodomain testis-specific protein)BRD3 (Bromodomain-containing protein 3)BRD2 (Bromodomain-containing protein 2)
Beyond the preview
Go deeper on mivebresib (AbbVie Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mivebresib (AbbVie Inc.).